HIV-infected adults diagnosed with age-related diseases at similar ages as uninfected

November 11, 2014

New research from the Johns Hopkins Bloomberg School of Public Health suggests that HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.

The findings appeared online last month in the journal Clinical Infectious Diseases.

Researchers say these findings can help reassure HIV-infected patients and their health care providers.

"We did not find conclusive evidence to suggest that screening for these diseases should occur at younger ages in HIV-infected compared with uninfected adults," says Keri N. Althoff, PhD, MPH, an assistant professor in the Department of Epidemiology at the Bloomberg School and lead author of the study.

Using data from 98,687 HIV-infected and uninfected adults in the Veterans Aging Cohort Study from April 1, 2003, to Dec. 31, 2010, the researchers were able to compare the ages at which each group was diagnosed with heart attacks, kidney failure and cancers unrelated to AIDS. Althoff and her colleagues found that HIV-infected adults were diagnosed with kidney failure, on average, when they were six months younger than the group without HIV. There were no statistically significant age differences at diagnosis between infected and uninfected adults for heart attacks or cancers unrelated to AIDS.

The study also compared the risk of these age-related diseases in HIV-infected and uninfected adults. Similar to previous studies, HIV-infected adults appear to be at an increased risk of these diseases, but the magnitude of the increase in risk was smaller than has been reported in many of the previous studies, likely due to this study's ability to adjust for factors such as race, gender, obesity, smoking, diabetes, and depression, among others, influencing the risk in both HIV-infected and uninfected adults.

In the early years of the AIDS epidemic, HIV was a death sentence. But in recent years antiretroviral therapy (ART) has been proven highly effective at suppressing HIV viral replication and increasing longevity for people with HIV. A study published in December 2013 in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) shows that the life expectancy among HIV-infected adults is only a few years shy of the U.S. general population.

While HIV-infected people are living longer, there has been a contentious debate in medical circles about whether they are undergoing an accelerated aging process. People living with HIV have demanded a more rigorous study of whether and why this may be happening.

Just because the data show that the onset of these three diseases is similar between those with and without HIV doesn't mean those with HIV are just as healthy, Althoff cautions.

"Many HIV-infected adults feel older than their age," she says. "Our study looks at three important age-related diseases and we find no meaningful difference in age at diagnosis. But this isn't the whole story. We need more research to figure out what is going on."
"Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected vs. uninfected adults" was written by Keri N. Althoff, PhD, MPH; Kathleen A. McGinnis, DrPH, MS; Christina M. Wyatt, MD, MS; Matthew S. Freiberg, MD, MSc; Cynthia Gilbert, MA; Krisann K. Oursler, MD, MS; David Rimland, MD; Maria C. Rodriguez-Barradas, MD; Robert Dubrow, MD, PhD; Lesley S. Park MPH, MPhil; Melissa Skanderson, MSW; Meredith S. Shiels, PhD; Stephen J. Gange, PhD; Kelly A. Gebo, MD, MPH; and Amy C. Justice, MD, PhD for the Veterans Aging Cohort Study.

The Veterans Aging Cohort Study is supported by National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U24-AA022001, U24 AA022007 and U10 AA013566-completed); National Heart, Lung, and Blood Institute (R01-HL095136 and R01-HL090342); National Institute of Allergy and Infectious Diseases (U01-A1069918); National Institute of Mental Health (P30-MH062294); National Institute on Drug Abuse (R01DA035616); the National Cancer Institute (R01 CA173754); the Agency for Healthcare Research & Quality (R01-HS018372); and the Veterans Health Administration Office of Research and Development. The researchers were supported by the National Institute of Allergy and Infectious Diseases (K01-AI093197); the National Cancer Institute (F31-CA180775); the National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK056492); and the Intramural Research Program of the National Cancer Institute (MSS).

Johns Hopkins University Bloomberg School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to